What Are Hot Flashes?
Hot flashes are sudden episodes of intense heat sensation, predominantly in the face, neck, and chest, frequently accompanied by profuse sweating and skin flushing. They are the most common vasomotor symptom of menopause, affecting 60-80% of women during the menopausal transition.
Each episode typically lasts 1 to 5 minutes and may be followed by chills. When they occur during sleep, they are called night sweats and cause sleep fragmentation, daytime fatigue, and a significant reduction in quality of life.
Hot flashes generally begin in perimenopause, peak in the first 2 years after menopause, and gradually decrease. However, 10-15% of women continue experiencing hot flashes for more than 15 years after menopause, and average symptom duration is 7 to 10 years.
Vasomotor Symptom
Hot flashes result from dysregulation of the hypothalamic thermoregulatory center caused by the drop in estrogen, not simply from "heat".
Prolonged Duration
The average duration of vasomotor symptoms is 7-10 years, significantly longer than previously believed.
Quality-of-Life Impact
Moderate-to-severe hot flashes affect sleep, mood, concentration, sexual function, and work productivity.
Pathophysiology
Hot flashes result from dysregulation of the thermoregulatory center in the hypothalamus. Under normal conditions, body temperature is maintained within a narrow range (the thermoneutral zone). At menopause, the drop in estrogen narrows this zone, só that small elevations in body temperature trigger heat-dissipation mechanisms — cutaneous vasodilation and sweating.
The central mechanism involves the KNDy neurons (kisspeptin, neurokinin B, and dynorphin) in the infundibular nucleus of the hypothalamus. These neurons are hypertrophied in the absence of estrogen and release neurokinin B (NKB), which activates NK3R receptors in the thermoregulatory center, triggering the hot flash.
This recent discovery led to the development of NK3R receptor antagonists (fezolinetant), a new nonhormonal therapeutic class that acts directly on the mechanism of hot flashes. Other neurotransmitters involved include norepinephrine (facilitator) and serotonin (modulator), explaining the efficacy of SSRIs/SNRIs as nonhormonal treatments.
Symptoms
Hot flashes are sudden waves of intense heat that ascend from chest to neck and face. Intensity ranges from mild discomfort to disabling episodes with profuse sweating. Frequency ranges from sporadic to more than 20 episodes a day.
Manifestations of Hot Flashes
- 01
Sudden sensation of heat
Intense heat in the face, neck, and chest, lasting 1-5 minutes. May be preceded by a sensation of pressure in the head.
- 02
Sweating
Profuse sweating, especially on the face and chest. In severe episodes, clothing can become soaked.
- 03
Skin flushing
Visible cutaneous vasodilation, with redness on the face and chest (flushing).
- 04
Post-flash chills
Cold sensation and chills after the episode, from sweat evaporation and reflex vasoconstriction.
- 05
Night sweats
Nocturnal hot flashes that trigger awakenings, bedclothes changes, and severe sleep fragmentation.
- 06
Palpitations
Reflex tachycardia during the episode, which can provoke anxiety and worry in uninformed patients.
Diagnosis
Diagnosis of menopausal hot flashes is clinical, based on a characteristic history in women in the menopausal transition age range (45-55 years). Tests are not needed for diagnosis in women with a typical presentation.
Measurement of FSH can be useful in women with a previous hysterectomy (without menstruation as a reference) or with atypical age. FSH values above 30 mIU/mL suggest menopause. It is important to rule out other causes of hot flashes, especially hyperthyroidism, pheochromocytoma, carcinoid, and drug effects.
🏥Differential Diagnosis of Hot Flashes
- 1.Hyperthyroidism: measure TSH and free T4
- 2.Pheochromocytoma: if hot flashes are associated with paroxysmal hypertension and headache
- 3.Carcinoid syndrome: if hot flashes are associated with diarrhea and persistent facial flushing
- 4.Drug effect: tamoxifen, GnRH analogs, opioids, niacin
- 5.Anxiety disorders: panic attacks may mimic hot flashes
- 6.Tuberculosis or lymphoma: isolated night sweats with fever and weight loss
DIFFERENTIAL DIAGNOSIS
Differential Diagnosis
Hypothyroidism
Read more →- Cold intolerance (not heat)
- Fatigue, weight gain, constipation
- Elevated TSH
Diagnostic Tests
- TSH and free T4
Autonomic nervous system modulation as an adjuvant to thyroid hormone treatment
Pheochromocytoma
- Hot flashes with paroxysmal hypertension
- Pulsatile headache during episodes
- Intense tachycardia
- Hypertensive crisis
- Family history of pheochromocytoma
Diagnostic Tests
- 24-h urinary or plasma metanephrines
- Abdominal CT
Not applicable in the investigation phase; requires surgical treatment
Carcinoid Syndrome
- Persistent or episodic facial flushing
- Episodic diarrhea
- Bronchospasm
- Persistent facial flushing with diarrhea
Diagnostic Tests
- 24-h urinary 5-HIAA
- Serum chromogranin A
No specific role; the condition requires oncologic treatment
Generalized Anxiety
Read more →- Episodes of heat associated with distress
- Palpitations and sweating without typical thermal phase
- Persistent excessive worry
Diagnostic Tests
- Clinical assessment
- Anxiety scales (GAD-7)
- Exclusion of organic causes
Moderate evidence for anxiety reduction; possible autonomic nervous system modulation
Lymphoma (Night Sweats)
- Intense night sweats associated with fever and weight loss
- Palpable lymphadenopathy
- Progressive fatigue
- Fever + night sweats + weight loss (B symptoms)
Diagnostic Tests
- Complete blood count
- LDH
- Staging CT
May help manage symptoms during oncologic treatment
Hypothyroidism
Hypothyroidism rarely causes typical hot flashes — on the contrary, it causes cold intolerance. However, subclinical hypothyroidism can alter the hormonal profile and precipitate atypical vasomotor symptoms. Women in the menopausal age range also have a higher prevalence of hypothyroidism, and the two conditions can coexist.
TSH measurement is mandatory in the initial evaluation of hot flashes to rule out thyroid dysfunction. Hypothyroidism treated with adequate levothyroxine generally does not cause hot flashes; if they persist after thyroid optimization, a menopausal etiology is confirmed.
Pheochromocytoma
Pheochromocytoma is an adrenal gland tumor that releases catecholamines paroxysmally, causing episodes of hypertension, headache, sweating, and tachycardia — a picture that can be confused with hot flashes. The key clinical differentiator is intense paroxysmal hypertension, which does not occur in menopausal hot flashes.
Clinical suspicion should be raised when hot flashes accompany intense pulsatile headache, severe hypertension, or a positive family history. Plasma or urinary metanephrine measurement is the screening test of choice, with high sensitivity.
Generalized Anxiety
Panic attacks and generalized anxiety can cause episodes of heat, sweating, and palpitations that mimic hot flashes. Differentiation is based on context: typical hot flashes arise spontaneously, with an ascending heat wave and 1-5 minute duration; anxiety episodes generally pair with an identifiable emotional trigger and respiratory symptoms.
Anxiety and hot flashes frequently coexist in perimenopause. In this context, medical acupuncture can be useful — with mixed evidence for hot-flash reduction and benefit in anxiety management — making it a complementary option to be considered case by case.
Treatment
Hormone therapy (HT) with estrogen is the most effective treatment for hot flashes, reducing frequency and intensity by 75-95%. For women with contraindications or who prefer to avoid hormones, effective nonhormonal options are available.
THERAPEUTIC OPTIONS FOR HOT FLASHES
| TREATMENT | EFFICACY | MAIN INDICATION |
|---|---|---|
| Hormone therapy (estrogen) | 75-95% reduction | Moderate-to-severe hot flashes without contraindications |
| Fezolinetant (NK3R antagonist) | 60-70% reduction | First-line nonhormonal option |
| SSRIs/SNRIs (paroxetine, venlafaxine) | 40-65% reduction | Contraindication to HT or nonhormonal preference |
| Gabapentin/pregabalin | 40-60% reduction | Hot flashes with insomnia or associated pain |
| Oxybutynin | 60-80% reduction | Effective nonhormonal alternative |
| Behavioral therapies (CBT) | 40-50% reduction | Adjunct or preference for nonpharmacologic approaches |
Acupuncture as Treatment
Acupuncture is one of the most studied complementary therapies for menopausal hot flashes. The literature includes several randomized clinical trials and systematic reviews, with results suggesting benefit in subgroups, though with relevant methodologic heterogeneity (differences in protocol, type of control — sham vs. waitlist — and outcomes). Evidence strength is limited to moderate.
Proposed mechanisms include autonomic nervous system modulation (sympathovagal rebalancing), regulation of hypothalamic neurons involved in thermoregulation, release of beta-endorphins, and modulation of central norepinephrine and serotonin levels. Thermography studies show that acupuncture can stabilize the hypothalamic thermoneutral zone.
Systematic reviews — including one published in BMJ Open aggregating data from several hundred women — suggest acupuncture can reduce hot flash frequency compared with controls, with effects described for several months after treatment ends. However, the MsFLASH trial (Ee et al., JAMA 2016) did not demonstrate acupuncture superiority over sham (placebo needling), highlighting heterogeneity of findings. Evidence level is moderate, with methodologic heterogeneity across studies. Acupuncture is an option particularly evaluated by breast cancer survivors, who frequently have contraindications to hormone therapy.
Prognosis
Hot flashes are a self-limited condition in most women, though duration is significantly longer than was previously believed. The SWAN study (Study of Women's Health Across the Nation) showed median hot flash duration is 7.4 years, with 10-15% of women having symptoms for more than 15 years.
With adequate treatment — hormonal or nonhormonal — most women achieve satisfactory symptom control. Hormone therapy can be maintained as long as benefits outweigh risks, with annual reassessment.
Moderate-to-severe hot flashes carry greater cardiovascular risk, lower bone mineral density, and cognitive impairment, suggesting they are not just a comfort symptom but may be a marker of overall menopausal health.
Myths and Facts
Myth vs. Fact
Hormone therapy is dangerous and should be avoided
For healthy women under 60 or within 10 years of menopause, current guidelines hold that hormone therapy benefits tend to outweigh risks in many cases, with small absolute risk in selected populations. The decision should be individualized with the gynecologist, weighing personal and family history.
Hot flashes only last 1-2 years
Average duration is 7-10 years, and 10-15% of women have hot flashes for more than 15 years. Underestimating duration can lead to insufficient treatment.
Soy supplements resolve hot flashes
Soy isoflavones have limited efficacy — 20-30% reduction in frequency — significantly inferior to hormone therapy. They may be useful for mild symptoms but are insufficient for moderate-to-severe hot flashes.
Hot flashes are just a nuisance with no health consequences
Moderate-to-severe hot flashes carry greater cardiovascular risk, osteoporosis, and cognitive impairment. Adequate treatment can offer benefits beyond comfort.
When to Seek Help
Every woman with hot flashes affecting quality of life should discuss therapeutic options with her physician. There is no need to "endure" symptoms when safe and effective treatments are available.
Frequently Asked Questions
Hot flashes result from dysregulation of the hypothalamic thermoregulatory center caused by falling estrogen. The estrogen drop hyperactivates hypothalamic KNDy neurons, which release neurokinin B. This activates NK3R receptors and triggers the heat wave. This specific mechanism led to new treatments such as fezolinetant.
Proposed mechanisms include autonomic nervous system modulation (sympathovagal rebalancing), beta-endorphin release, and modulation of central norepinephrine and serotonin levels, with potential effect on hypothalamic neurons involved in thermoregulation. Some thermography studies suggest acupuncture may help stabilize the hypothalamic thermoneutral zone. These mechanisms remain largely hypotheses, supported by experimental data and still being consolidated.
Studies show benefits begin after 4 to 6 sessions and continue improving over 10 to 12 sessions. Residual effect can persist up to 6 months after treatment ends. Monthly or bimonthly maintenance sessions can prolong benefits.
For healthy women under 60 and within 10 years of menopause, international menopause guidelines consider hormone therapy an option with a generally favorable risk-benefit profile and good clinical efficacy (literature reports reductions of 75 to 95% of hot flashes, varying by study, dose, and population). Absolute risks tend to be low in selected populations but not nil (thromboembolism, breast cancer with prolonged use of estrogen-progestogen combinations, among others). The decision should be individualized with the gynecologist, weighing the patient's history.
Yes. Effective nonhormonal options include fezolinetant (NK3R antagonist, FDA-approved in 2023), SSRIs and SNRIs (paroxetine, venlafaxine), gabapentin, pregabalin, and oxybutynin. Medical acupuncture is indicated as a complement or alternative for women with hormonal contraindications, such as breast cancer survivors.
Average duration is 7.4 years (SWAN study), significantly longer than was believed. About 10 to 15% of women have hot flashes for more than 15 years after menopause. Women whose hot flashes begin before menopause, in perimenopause, tend to have more prolonged symptoms.
Yes. Systematic reviews — including one published in BMJ Open aggregating data from several hundred women — suggest acupuncture can reduce hot flash frequency compared with controls, with effects described for several months after treatment. Evidence level is moderate, with methodologic heterogeneity across studies (sham controls vs. waitlists, protocol differences). Readers who want to check the primary basis can consult the main reviews in the library.
Yes. Moderate-to-severe hot flashes carry greater cardiovascular risk, lower bone mineral density, and cognitive impairment. Sleep fragmentation from night sweats affects metabolism, mood, and cognitive function. Adequate treatment can offer benefits beyond comfort.
Soy isoflavones have modest efficacy — 20 to 30% frequency reduction — significantly inferior to hormone therapy (75 to 95%) and to the main nonhormonal treatments. They can be useful for mild hot flashes or as a complement. Quality products with standardized doses are important for any benefit.
Yes. Women with a history of hormone-dependent breast cancer often present with intense hot flashes induced by tamoxifen or aromatase inhibitors and have an absolute contraindication to hormone therapy. In this context, medical acupuncture offers a complementary option with a good safety profile; hot flash evidence is mixed, requiring individualized expectations.
Related Reading
Deepen your knowledge with related articles